Literature DB >> 26904211

Outcomes of total cavopulmonary connection for single ventricle palliation.

Minghui Zou1, Yanfei Wang1, Hujun Cui1, Li Ma1, Shengchun Yang1, Yuansheng Xia1, Weidan Chen1, Xinxin Chen1.   

Abstract

BACKGROUND: The aim of this study was to review the early and mid-term outcomes of the total cavopulmonary connection (TCPC) procedure and evaluate risk factors for prolonged pleural effusions.
METHODS: The clinical records of 82 consecutive patients, who underwent a TCPC operation between January 2008 and December 2013, were reviewed for incidence of prolonged pleural effusions, duration of ventilation time and pleural drainage, length of intensive care unit (ICU) stay, and early and mid-term morbidity and mortality.
RESULTS: The median age at surgery was 3.0 years. The main single ventricle diagnoses included 18 cases of a double-inlet single ventricle, 17 cases of heterotaxy, 16 cases of tricuspid atresia, 4 cases of mitral atresia, 12 cases of unbalanced complete atrioventricular canal (CAVC), 5 cases of double-outlet right ventricle (DORV) combined with ventricular septal defect (VSD) and pulmonary stenosis (PS), 4 cases of transposition of the great arteries (TGA) combined with VSD and PS, 4 cases of corrected transposition of great arteries (cTGA) combined VSD and PS, and 2 cases of criss-cross heart. Preoperative mean pulmonary artery pressure (mPAP) was 13.66±2.21 mmHg with 23.2% (n=19) higher than 15 mmHg. A total of 61 (74.4%) patients underwent a fenestration. The perioperative mortality was 4.9%. The median duration of pleural effusion was 10 days (range, 3-80 days), and prolonged pleural effusions occurred in 16 (19.5%) patients. Multivariable analysis revealed that mPAP >15 mmHg was independently associated with prolonged pleural effusions (OR, 8.33; 95% CI, 2.33-29.74; P=0.001), and creation of a fenestration was associated with decreased odds of effusion (OR, 0.21; 95% CI, 0.06-0.74; P=0.015). Five-year estimated Kaplan-Meier survival of two-stage TCPC was significantly higher than that of one-stage group(96.7% vs. 79.7%, P=0.023). Patients with heterotaxy or obstructed totally anomalous pulmonary venous connection (TAPVC) had significantly worse mid-term survival.
CONCLUSIONS: Staged TCPC improved the early and mid-term survival of patients with a single ventricle. mPAP >15 mmHg was independently associated with prolonged pleural effusions and a fenestration significantly associated with a lower odds of effusion.

Entities:  

Keywords:  Total cavopulmonary connection (TCPC); fenestration; heterotaxy; outcomes; totally anomalous pulmonary venous connection (TAPVC)

Year:  2016        PMID: 26904211      PMCID: PMC4740135          DOI: 10.3978/j.issn.2072-1439.2016.01.41

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  25 in total

1.  Fontan "Ten Commandments" revisited and revised.

Authors:  Herbert J Stern
Journal:  Pediatr Cardiol       Date:  2010-10-20       Impact factor: 1.655

2.  Fenestration during Fontan palliation: now the exception instead of the rule.

Authors:  Jorge D Salazar; Farhan Zafar; Kashif Siddiqui; Ryan D Coleman; David L S Morales; Jeffrey S Heinle; Joseph W Rossano; Emad B Mossad; Charles D Fraser
Journal:  J Thorac Cardiovasc Surg       Date:  2010-07       Impact factor: 5.209

3.  Fontan operation: a comparison of lateral tunnel with extracardiac conduit.

Authors:  Andrew C Fiore; Mark Turrentine; Mark Rodefeld; Palaniswamy Vijay; Theresa L Schwartz; Katherine S Virgo; Laurice K Fischer; John W Brown
Journal:  Ann Thorac Surg       Date:  2007-02       Impact factor: 4.330

4.  Inferior vena cava-pulmonary artery extracardiac conduit. A new form of right heart bypass.

Authors:  C Marcelletti; A Corno; S Giannico; B Marino
Journal:  J Thorac Cardiovasc Surg       Date:  1990-08       Impact factor: 5.209

5.  Baffle fenestration with subsequent transcatheter closure. Modification of the Fontan operation for patients at increased risk.

Authors:  N D Bridges; J E Lock; A R Castaneda
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

6.  Systemic-to-pulmonary collateral flow, as measured by cardiac magnetic resonance imaging, is associated with acute post-Fontan clinical outcomes.

Authors:  Andrew C Glatz; Jonathan J Rome; Adam J Small; Matthew J Gillespie; Yoav Dori; Matthew A Harris; Marc S Keller; Mark A Fogel; Kevin K Whitehead
Journal:  Circ Cardiovasc Imaging       Date:  2012-01-06       Impact factor: 7.792

7.  Factors influencing early and late outcome following the Fontan procedure in the current era. The 'Two Commandments'?

Authors:  Riad B M Hosein; Andrew J B Clarke; Simon P McGuirk; Massimo Griselli; Oliver Stumper; Joseph V De Giovanni; David J Barron; William J Brawn
Journal:  Eur J Cardiothorac Surg       Date:  2007-01-22       Impact factor: 4.191

8.  Improved current era outcomes in patients with heterotaxy syndromes.

Authors:  Petros V Anagnostopoulos; Jeffrey M Pearl; Courtney Octave; Mitchell Cohen; Angelika Gruessner; Erika Wintering; Michael F Teodori
Journal:  Eur J Cardiothorac Surg       Date:  2009-02-23       Impact factor: 4.191

Review 9.  Fontan circulation: success or failure?

Authors:  Blandine Mondésert; François Marcotte; François-Pierre Mongeon; Annie Dore; Lise-Andrée Mercier; Reda Ibrahim; Anita Asgar; Joaquim Miro; Nancy Poirier; Paul Khairy
Journal:  Can J Cardiol       Date:  2013-03-06       Impact factor: 5.223

10.  Fontan operation in the current era: a 15-year single institution experience.

Authors:  Jennifer C Hirsch; Caren Goldberg; Edward L Bove; Sepand Salehian; Timothy Lee; Richard G Ohye; Eric J Devaney
Journal:  Ann Surg       Date:  2008-09       Impact factor: 12.969

View more
  1 in total

1.  Risk Factors for Prolonged Pleural Effusion Following Total Cavopulmonary Connection Surgery: 9 Years' Experience at Fuwai Hospital.

Authors:  Qipeng Luo; Wei Zhao; Zhanhao Su; Yiwei Liu; Yuan Jia; Liang Zhang; Hongbai Wang; Yinan Li; Xie Wu; Shoujun Li; Fuxia Yan
Journal:  Front Pediatr       Date:  2019-11-07       Impact factor: 3.418

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.